ODYSSEY Outcomes: Alirocumab Reduces MACE, Non-fatal MI, Ischemic Stroke, and All-Cause Mortality in ACS Patients

Last updated: April 22, 2018 4:08 pm

Tarek Nafee, M.D.

Share

0 Min Read